{"status": "ok", "totalResults": 2, "articles": [{"source": {"id": null, "name": "FiercePharma"}, "author": "FiercePharma", "title": "Danaher to buy antibody expert Abcam for $5.7B - FiercePharma", "description": null, "url": "https://www.fiercepharma.com/pharma/after-catalent-buyout-wasnt-danaher-floats-24-share-acquire-uk-antibody-expert-abcam", "urlToImage": null, "publishedAt": "2023-08-28T13:18:11Z", "content": null}, {"source": {"id": "financial-times", "name": "Financial Times"}, "author": "Ethan Wu", "title": "The private capital overhaul arrives - Financial Times", "description": "The SEC argues sophisticated investors need protection, too", "url": "https://www.ft.com/content/fc2ec899-3a98-4b46-b239-b29f70f1330d", "urlToImage": null, "publishedAt": "2023-08-28T05:30:19Z", "content": "What is included in my trial?\r\nDuring your trial you will have complete digital access to FT.com with everything in both of our Standard Digital and Premium Digital packages.\r\nStandard Digital includ\u2026 [+1496 chars]"}]}